Back to Peptides
Skin & JointLow Risk

Sigumir

Also known as: Val-Glu-Pro-Arg, Joint bioregulator, Khavinson joint peptide

Half-life:
Unknown

Administration Routes

subcutaneous injectionoral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

A Khavinson bioregulator for bone and joint tissue. Complements Cartalax with activity in both cartilage and bone compartments; studied for degenerative joint disease and osteoporosis.

Primary Research Areas

  • joint tissue repair
  • bone and cartilage support
  • anti-inflammatory (joint)
  • mobility improvement

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian joint peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Sigumir

No active associated providers listed yet.